Open AccessMycophenolate revisited
Author(s) -
Gelder Teun,
Hesselink Dennis A.
Publication year - 2015
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/tri.12554
Subject(s) - mycophenolic acid , mycophenolate , medicine , drug , azathioprine , pharmacology , population , innovator , transplantation , disease , environmental health , intellectual property , computer science , operating system
Summary The patent of mycophenolate mofetil ( MMF ) has expired, and for enteric‐coated mycophenolate sodium ( EC ‐ MPS ), this will happen in 2017. In the twenty years these drugs have been used, they have become extremely popular. In this review, the reasons for the popularity of mycophenolate are discussed, including the benefits compared to azathioprine. MMF and EC ‐ MPS are therapeutically equivalent. Although neither is considered to be a narrow therapeutic index drug, this should not lead to careless switching between the innovator drug and generic formulations, or between one generic formulation and another. The pipeline of new immunosuppressive drugs is dry, and it is very likely that we will be using mycophenolate for many more years to come as a first‐line immunosuppressive drug in our transplant population. Whether or not the development of donor‐specific anti‐ HLA antibodies is related to drug exposure (mycophenolic acid concentrations) remains to be investigated.